To answer PedsEndoPhilly's question specifically:

From a clinical standpoint, Canadian GLP-1 coverage is an area where we have good evidence.

The short answer: baseline labs + quarterly monitoring is the standard of care.

The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.

Same experience here with Canadian GLP-1 coverage . lisa_labSD described it perfectly.

OP here — wow, did not expect this much response! Thank you all for the thoughtful replies on Canadian GLP-1 coverage .

To answer lisa_labSD: I started tracking everything in a spreadsheet from day 1.

Quick update: I will post a proper update thread soon. Thanks again for the evidence-based discussion — this is exactly why I posted in a science-based community. 🙏

Subscribing to this thread. Canadian GLP-1 coverage is exactly what I've been researching. 🙏

+1 to Dr.SleepRoch. Especially the point about "Canadian GLP-1 coverage anyone is not t..." — I have seen the same in my own experience with Canadian GLP-1 coverage .